- Home
- SNTG vs APM Comparison
SNTG vs APM Comparison
Compare SNTG & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- APM
- Stock Information
- Founded
- SNTG 2009
- APM 2010
- Country
- SNTG China
- APM United Kingdom
- Employees
- SNTG N/A
- APM N/A
- Industry
- SNTG Finance: Consumer Services
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- APM Health Care
- Exchange
- SNTG Nasdaq
- APM Nasdaq
- Market Cap
- SNTG 5.2M
- APM 5.6M
- IPO Year
- SNTG 2021
- APM 2018
- Fundamental
- Price
- SNTG $1.68
- APM $0.99
- Analyst Decision
- SNTG
- APM
- Analyst Count
- SNTG 0
- APM 0
- Target Price
- SNTG N/A
- APM N/A
- AVG Volume (30 Days)
- SNTG 21.0K
- APM 138.3K
- Earning Date
- SNTG 05-06-2025
- APM 05-06-2025
- Dividend Yield
- SNTG N/A
- APM N/A
- EPS Growth
- SNTG N/A
- APM N/A
- EPS
- SNTG N/A
- APM 0.00
- Revenue
- SNTG $146,472.00
- APM N/A
- Revenue This Year
- SNTG N/A
- APM $157,729.10
- Revenue Next Year
- SNTG N/A
- APM N/A
- P/E Ratio
- SNTG N/A
- APM $270.99
- Revenue Growth
- SNTG N/A
- APM N/A
- 52 Week Low
- SNTG $1.43
- APM $0.46
- 52 Week High
- SNTG $3.97
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SNTG 48.37
- APM 51.54
- Support Level
- SNTG $1.55
- APM $0.79
- Resistance Level
- SNTG $1.77
- APM $0.97
- Average True Range (ATR)
- SNTG 0.10
- APM 0.12
- MACD
- SNTG 0.01
- APM 0.02
- Stochastic Oscillator
- SNTG 73.91
- APM 33.74
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.